RS-67333

RS-67333 is one of the most widely cited experimental 5-HT4 receptor agonists in cognitive neuroscience, valued because it combines high affinity, good brain penetration, and behavioural efficacy in rodents. The 5-HT4 receptor is positively coupled to adenylyl cyclase, and its activation in the hippocampus and cortex both enhances acetylcholine release and promotes synaptic plasticity, which provides a rational basis for the memory-enhancing effects observed with the compound.

The strongest translational interest in RS-67333 comes from Alzheimer's disease models. In the 5XFAD transgenic mouse, chronic administration begun during the pre-symptomatic phase reduced amyloid plaque burden and soluble amyloid-beta, lowered hippocampal astrogliosis and microgliosis, transiently raised sAPPalpha in cerebrospinal fluid and brain, and reversed novel-object-recognition deficits; a selective 5-HT4 antagonist blocked these benefits, confirming receptor specificity ^[1]. A separate 5XFAD study found that four months of treatment (but not two months) improved hippocampus-dependent learning in the olfactory tubing maze and reduced amyloid pathology and neuroinflammation, most markedly in the entorhinal cortex, underscoring that treatment duration is decisive ^[2].

RS-67333 has also been used to dissect memory circuitry, for example in studies of hippocampal serotonin-cannabinoid interactions during spatial and object novelty detection, where intra-CA1 microinjection modulated memory encoding ^[3]. The receptor mechanism these tools interrogate has since been validated in humans with the clinically used 5-HT4 agonist prucalopride, which improved verbal learning and memory in healthy volunteers, lending weight to the idea that 5-HT4 agonism is a genuine cognitive target rather than a rodent-only phenomenon ^[4].

RS-67333 has not undergone formal human safety evaluation, so its tolerability profile in people is unknown and it should be regarded strictly as a laboratory reagent. As a class, brain-penetrant 5-HT4 agonists carry the theoretical liabilities common to serotonergic and prokinetic compounds, including gastrointestinal acceleration and, for some non-selective older agents, cardiac repolarization effects; RS-67333 itself has not been reported to prolong the QT interval, but its cardiac profile is not characterized to clinical standards. No dosing, drug-interaction, or long-term toxicity data exist for humans.

RS-67333 emerged in the mid-1990s from efforts to develop selective 5-HT4 ligands, and it was quickly adopted by academic laboratories as a benchmark central 5-HT4 agonist. Its research profile expanded substantially after work by French groups at Montpellier and Marseille demonstrated that chronic 5-HT4 activation could shift amyloid precursor protein processing and slow amyloid accumulation in transgenic mice, positioning the compound as a proof-of-concept for 5-HT4 based Alzheimer's therapeutics. It has remained an investigational tool rather than a drug candidate, informing the design of later CNS-directed 5-HT4 agonists.

Within cognitive and Alzheimer's neuroscience, RS-67333 is regarded as the archetypal pro-cognitive 5-HT4 agonist and is frequently the positive control against which newer molecules are compared. In nootropic communities it is discussed as a theoretically attractive but practically unavailable compound, since it has never been produced as a consumer product and lacks any human data. Its reputation rests on a coherent and much-replicated preclinical story rather than on clinical validation.